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Abstract
The malaria parasite Plasmodium falciparum exports several hundred proteins into the infected erythrocyte that are involved
in cellular remodeling and severe virulence. The export mechanism involves the Plasmodium export element (PEXEL), which
is a cleavage site for the parasite protease, Plasmepsin V (PMV). The PMV gene is refractory to deletion, suggesting it is
essential, but definitive proof is lacking. Here, we generated a PEXEL-mimetic inhibitor that potently blocks the activity of
PMV isolated from P. falciparum and Plasmodium vivax. Assessment of PMV activity in P. falciparum revealed PEXEL cleavage
occurs cotranslationaly, similar to signal peptidase. Treatment of P. falciparum–infected erythrocytes with the inhibitor
caused dose-dependent inhibition of PEXEL processing as well as protein export, including impaired display of the major
virulence adhesin, PfEMP1, on the erythrocyte surface, and cytoadherence. The inhibitor killed parasites at the trophozoite
stage and knockdown of PMV enhanced sensitivity to the inhibitor, while overexpression of PMV increased resistance. This
provides the first direct evidence that PMV activity is essential for protein export in Plasmodium spp. and for parasite survival
in human erythrocytes and validates PMV as an antimalarial drug target.
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Introduction
Each year malaria parasites cause several hundred million
infections and over 650,000 deaths [1]. Plasmodium falciparum causes
the most lethal malaria and is endemic in Africa [2]. Plasmodium
vivax causes most malarial deaths outside Africa and is associated
with liver-stage hypnozoites [3]. Although chloroquine and
artemisinin have been effective antimalarials, their decreasing
efficacy [4,5] emphasizes the need for therapies against novel
targets shared by both Plasmodium spp.
Malaria parasites develop in erythrocytes within a parasitophor-
ous vacuole and export over 450 proteins to the cell (reviewed in
[6,7]). Export utilizes an N-terminal motif called the Plasmodium
export element (PEXEL; RxLxE/Q/D) [8] or Vacuolar transport
signal (VTS) [9]. Exported proteins are cleaved in the PEXEL after
Leu (RxLQ) in the endoplasmic reticulum (ER) [10], which
requires the conserved Arg and Leu residues [11]. PEXEL cleavage
is performed by the aspartyl protease Plasmepsin V (PMV) [12,13].
PEXEL-containing proteins and PMV are conserved in all
Plasmodium spp. [8,14–16]. Repeated attempts to disrupt the PMV
gene have failed, suggesting it is essential [12,13,16], but direct and
decisive proof is still lacking. A functional survey of P. falciparum
exported proteins indicated that 25% or more are essential for
parasite survival in human erythrocytes [17]. The current P.
falciparum PEXEL exportome is predicted to be 463 proteins [18];
thus, possibly 100 or more exported parasite proteins are required
for development in erythrocytes.
Some exported proteins lack a PEXEL, for example, skeleton
binding protein 1 (SBP1) and the major virulence adhesin family
known as P. falciparum erythrocyte membrane protein 1 (PfEMP1).
PfEMP1 is expressed on the erythrocyte surface and mediates
cytoadherence to microvascular endothelia, causing severe malaria
[19]. PfEMP1 is thought not to be cleaved by PMV [18], but its
transport to, and expression on, the erythrocyte surface requires
exported PEXEL and PEXEL-negative proteins (reviewed in
[7,20]).
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Aspartyl proteases can be inhibited by transition-state isosteres
in which the scissile bond is replaced by a noncleavable moiety.
Examples include statine (Sta)-containing inhibitors and several
are now in clinical use [21].
Here, we developed a transition-state inhibitor that potently
blocks PMV from P. falciparum and P. vivax. The inhibitor
demonstrates that PMV activity is essential for protein export,
PfEMP1 surface display, cytoadherence, and parasite survival in
human erythrocytes.
Results
PMV Is Highly Conserved in Plasmodium
The PMV gene is present in all Plasmodium spp.; however, only
the P. falciparum enzyme (PfPMV; Pf3D7_1323500) has been
characterized. A multiple alignment of PfPMV with putative P.
vivax PMV (PvPMV; PVX_116695) indicated that they share
82.2% similarity, 54.7% identity (Figure S1). Both proteins are
predicted to contain a signal peptide, an aspartyl protease domain
with DTG and DSG residues defining the catalytic dyad, and a C-
terminal transmembrane domain (Figure 1A). Due to four
insertions, PfPMVHA is predicted to be approximately 7.5 kDa
larger than PvPMVHA (Figure 1A); however, following signal
peptide removal, PfPMVHA is predicted to be 8 kDa larger than
PvPMVHA.
To determine whether PvPMV is an ortholog of PfPMV, we
expressed it in P. falciparum fused to 36 hemagglutinin (HA) tags
(Figure 1A). As a positive control, we expressed PfPMV fused to
36 HA tags (Figure 1A) [13]. Expression of PfPMVHA and
PvPMVHA was confirmed by immunoblot using anti-HA
antibodies (Figure 1B). PvPMVHA was ,8 kDa smaller than
PfPMVHA, as predicted (Figure 1B).
PfPMV was previously localized to the ER using a mouse anti-
PfPMV antibody that colocalizes with BiP [16] and ERC [13]. To
further study PMV, we developed a rabbit antibody that was
specific for PfPMV (Figure 1C, compare lanes 1 and 2) and
colocalizes with the ER signal from the mouse PfPMV antibody
(Figure 1D, top) but does not cross-react with PvPMVHA (Figure
S2A). Using anti-HA antibodies, a strong perinuclear signal was
observed in parasites expressing PvPMVHA or PfPMVHA
(Figure 1D, middle panels, red). Both proteins colocalized with
rabbit anti-PfPMV antibodies, indicating the location was the ER
(Figure 1D). PvPMVHA also colocalized with ERC (Figure 1D,
bottom), as shown previously for PfPMVHA [13].
To investigate PvPMVHA activity, we affinity purified it, as well
as the PfPMVHA control, using anti-HA agarose, as previously
described [13,18]. Immunoblot with anti-HA and anti-PfPMV
antibodies showed that the purified proteins were species-specific
(Figure S2A). The proteins were incubated with a fluorogenic
peptide of nine amino acids that contained the PEXEL sequence
from knob-associated histidine-rich protein (KAHRP), and
efficient processing was observed by both enzymes (Figure 1E).
Cleavage of KAHRP by PfPMVHA was previously shown to
occur after Leu (RTLQ) by mass spectrometry [13], and this
position was also confirmed for PvPMVHA (Figure S2B–E). Km
values of 9.7 (63.0) and 11.7 (61.8) mM were calculated for
PvPMVHA and PfPMVHA, respectively (Figure S2F). In contrast,
no processing was observed when the PEXEL Arg and Leu
residues were mutated to Ala (ATAAQ), consistent with the
substrate specificity of PfPMV (Figure 1E). To verify that
processing was due to HA-tagged PMV rather than other co-
precipitated proteases, we expressed in P. falciparum a mutant of
PvPMVHA or PfPMVHA [13], where one or both catalytic Asp
residues were mutated to Ala (see Figure 1A,B). Following affinity
purification, the mutant enzymes were incubated with KAHRP
PEXEL peptides, but no processing was observed (Figure 1E; blue,
white), confirming that the PEXEL-dependent cleavage activity
observed for each protease was attributable only to HA-tagged
PMV.
The substrate specificity of PfPMV is restricted, such that even
minor changes to the PEXEL sequence markedly reduces cleavage
efficiency—that is, Arg to Lys (R.K) or Leu to Ile (L.I) [18]. We
assessed whether PvPMVHA shares this feature. Indeed,
PvPMVHA poorly cleaved peptides possessing R.K or L.I
mutations (Figure 1E; KTLAQ, RTIAQ). Collectively, these data
show that PvPMV localizes to the ER and cleaves the PEXEL
with the same restricted specificity as PfPMV.
While maintaining P. falciparum cultures overexpressing
PfPMVmutHA, we noticed a delay in growth, suggesting a
possible dominant negative phenotype, which has been reported
previously with a different PfPMV catalytic mutant [12]. A flow
cytometry-based growth assay revealed that parasites expressing
PfPMVmutHA with WR99210 selection grew to a parasitemia
2.6-fold less than parasites expressing a similar episomal construct,
encoding a mini PfEMP1 reporter fused to 36 HA tags
(miniVarHA) with WR99210 selection (p,.0001; Figure 1F). This
demonstrated that overexpression of inactive enzyme conveyed a
growth disadvantage, providing evidence that PMV is important
for parasite survival. Analysis of PMV protein levels in parasites
overexpressing the PMVHA transgenes indicated that PvPMVHA
and PvPMVmutHA had no effect on endogenous PfPMV levels;
however, overexpression of inactive PfPMVmutHA caused a clear
decrease in expression of the endogenous enzyme (Figure 1C,
compare lanes 1 and 4, and Aldolase loading controls), indicating
a negative feedback mechanism occurs in these parasites.
Rational Design of a PMV Inhibitor
The conserved P3 Arg and P1 Leu residues in the PEXEL (see
Figure 2A for a description of nomenclature) are crucial for PMV
activity [12,13]. We developed a homology model and designed
compounds with a transition-state isostere that mimics the natural
PEXEL substrate with the aim of inhibiting PMV. One mimetic,
WEHI-916 (Figure 2B), consisted of Arg that could bind in the S3
pocket of PfPMV, Val that would position in the S2 pocket, and
Leu-Statine (Leu-Sta), to engage the S1 pocket and inhibit both
catalytic Asp residues of PMV (Figure 2C).
As control compounds, we synthesized analogs similar to 916
but that mimic noncleavable PEXEL mutant substrates, with the
Author Summary
To survive within human red blood cells, malaria parasites
must export a catalog of proteins that remodel the host
cell and its surface. This enables parasites to acquire
nutrients from outside the cell and to modify the cell
surface in order to evade host defenses. Protein export
involves proteolytic cleavage of the Plasmodium Export
Element (PEXEL) by the aspartyl protease Plasmepsin V. We
report here the development of a small molecule inhibitor
that closely mimics the natural PEXEL substrate and blocks
the activity of Plasmepsin V from the malarial parasites
Plasmodium falciparum and Plasmodium vivax. The inhib-
itor impairs export and cellular remodeling and kills P.
falciparum at the ring-trophozoite transition, providing
direct evidence that Plasmepsin V activity is essential for
export of PEXEL proteins and parasite survival within the
host. These findings validate Plasmepsin V as a highly
conserved antimalarial drug target.
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aim that they would be poor PMV inhibitors; the first replaced
the P3 Arg with Lys (R.K; WEHI-024) and the second replaced
the P1 Leu with Ile (L.I; WEHI-025; Figure 2B). These analogs
were designed on the basis that mutations of the conserved
PEXEL residues R.K or L.I almost completely inhibit cleavage
by PMV (Figure 1E and [18]) and should therefore have lower
affinity for PMV.
Each compound was incubated with PfPMVHA in the presence
of KAHRP PEXEL peptides. WEHI-916 (henceforth 916)
potently inhibited PEXEL cleavage by PfPMVHA with a 50%
inhibitory concentration (IC50) of 20 nM (Figure 2D). In contrast,
WEHI-024 and WEHI-025 (henceforth 024 and 025, respectively)
had weak activity (IC50.100 mM and 1.11 mM, respectively;
Figure 2D). 916 inhibited PvPMVHA with an IC50 of 24 nM,
whereas 024 and 025 again had weak activity (Figure 2D).
To investigate potential off-target activity against human
aspartyl proteases, the compounds were assessed against beta-
secretase (BACE-1), for which PMV has distant relatedness [12],
Cathepsin D, and two human cell lines; the compounds displayed
poor activity (IC50.100 mM for BACE-1; 25 mM for Cathepsin
D) and had negligible toxicity against human HEpG2 and
fibroblast cell lines (Figure 2D). Collectively, this demonstrated
that 916 potently inhibited PMV and had low off-target activity
against BACE-1 and Cathepsin D, whereas the closely related
analogs 024 and 025 were poorly active.
WEHI-916 Inhibits PMV in P. falciparum–Infected
Erythrocytes
To assess whether 916 could inhibit PMV in P. falciparum–
infected erythrocytes, parasites expressing the PEXEL protein P.
Figure 1. PMV conservation and expression. (A) Structure and size of PMVHA proteins used in this study. Catalytic dyad residues DTG/DSG are
shown including Asp to Ala mutations* in red. TM, transmembrane domain. (B) Immunoblot of infected erythrocytes with a-HA antibodies shows
expression of PMVHA proteins in P. falciparum. Sizes indicate that the signal peptides were removed (PfPMVHA, 69.1 kDa; PvPMVHA, 60.9 kDa). (C)
Immunoblotting of infected erythrocytes with rabbit a-PfPMV antibodies (Ra-PfPMV) validates they are specific for PfPMV. Endogenous PfPMV is the
lower band (lanes 1, 3, 4, 5), and the larger band corresponds to 36HA-tagged PfPMV (lanes 2, 4). Aldolase is a loading control in (B) and (C) and
shows slight overloading of some lanes compared to others. (D, Top) Immunofluorescence micrographs show rabbit a-PfPMV antibodies (Ra-PfPMV,
green) label PfPMV in the ER. Colocalizations were performed with mouse a-PfPMV antibodies (Ma-PfPMV, red), shown previously to label PMV in the
ER [16]. (Middle) a-HA antibodies (red) label PfPMVHA (Top) and PvPMVHA (Bottom) in the parasite ER. (Bottom) a-HA antibodies (red) label PvPMVHA
in the ER, as shown by clocalization with ERC (green). (E) Immunopurified PfPMVHA and PvPMVHA cleave KAHRP peptides containing the PEXEL
sequence RTLAQ but not peptides containing point mutations R.K, L.I, or RL.A. Pf and Pv PMVmutHA proteins with catalytic D.A mutations did
not cleave the KAHRP RTLAQ peptide. (F) Overexpression of PfPMVmutHA from episomes in P. falciparum 3D7 impairs growth relative to expression
of a similar episomal construct encoding a mini PfEMP1HA reporter (miniVarHA). Parasites expressing episomes were selected on 5 nM WR99210
(WR). Two starting inocula were used in triplicate wells, and parasitaemia was determined at 72 h. *p,.0001 (t test). Data are mean 6 SEM from
duplicate experiments.
doi:10.1371/journal.pbio.1001897.g001
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falciparum erythrocyte membrane protein 3 (PfEMP3) fused to
green fluorescent protein (GFP) [13] were treated with increasing
concentrations of inhibitor, and PEXEL processing was evaluated
by immunoblot. A dose-dependent increase in unprocessed
PfEMP3-GFP was observed (black arrow, Figure 3A), which was
the same size as uncleaved PEXEL R.A mutant PfEMP3-GFP
(Figure 3A) [13]. The level of PEXEL-cleaved protein (blue arrow,
Figure 3A) did not quantitatively reflect the degree of PMV
inhibition, as inhibitor was added well after PEXEL processing
and export of PfEMP3-GFP had initiated. A GFP-only band,
representing degraded chimera in the food vacuole, was also
observed at,26 kDa (Figure 3A). Together, this demonstrated that
PEXEL processing was impaired by 916 treatment and that
engagement of PMV occurred in P. falciparum–infected erythrocytes.
To understand the timing required for PMV inhibition in P.
falciparum, parasites were treated with 916 for 1–5 h, and cleavage
was evaluated by immunoblot. No effect was seen after 1 h;
however, uncleaved PfEMP3-GFP increased between 2 and 5 h
(Figure 3B), indicating 916 accessed the parasite ER slowly.
Inhibition of PfEMP3-GFP cleavage by 916 was rescued following
culture in inhibitor-free medium, to approximately 50% after 2 h
(Figure S3A), indicating that cleavage inhibition was reversible or
that additional active PMV was synthesized during the experiment.
We next assessed whether the control analogs 024 and 025,
which were poor inhibitors of PMV in vitro, had an effect on
PEXEL cleavage in parasites. Although a dose-dependent effect
was again observed with 916, analogs 024 and 025 had no effect
on PEXEL processing of PfEMP3-GFP or KAHRP-GFP, even at
50 mM (Figure 3C). In the case of KAHRP-GFP, 916 treatment
caused accumulation of both uncleaved (black arrow) and signal
peptide-cleaved (red arrow) protein, which were the same size as
bands observed for PEXEL R.A mutant KAHRP-GFP
(Figure 3C, right). These bands were shown previously to be
uncleaved and signal peptide-cleaved KAHRP-GFP, respectively,
by mass spectrometry [11].
As 916 treatment caused accumulation of both uncleaved and
signal peptide-cleaved species of PEXEL proteins, the potential for
off-target effects against signal peptidase was investigated using
parasites expressing SERA5s-GFP. This protein contains a signal
peptide but lacks a PEXEL and is efficiently secreted to the
parasitophorous vacuole (Figure S3B). 916 treatment did not
impair processing of the signal peptide from SERA5s-GFP
(Figure 3D, see position of black arrow), indicating it cannot
inhibit signal peptidase. Taken together, this shows that 916 can
effectively inhibit PMV, but not signal peptidase, in P. falciparum–
infected erythrocytes and that 024 and 025 have no affect on PMV
or signal peptidase activity at concentrations up to 50 mM.
PMV Acts Cotranslationaly at the ER in P. falciparum
The rate of PEXEL protein synthesis, ER import, and
processing by PMV in P. falciparum is unknown. We evaluated
these processes by radiolabeling parasite proteins in culture for
0.5–15 min before immunoprecipitating PfEMP3-GFP with
anti-GFP agarose, visualizing bands by autoradiography and
quantifying them by densitometry. Labeled PfEMP3-GFP became
evident 1 min after addition of label to the culture medium and
increased exponentially throughout the experiment (Figures 3E
and S3D). Uncleaved PfEMP3-GFP (black arrow) was faint and
the major species was a doublet of approximately 33 kDa (red
arrow; signal peptide-cleaved) and 29 kDa (blue arrow; PEXEL-
cleaved; Figure 3E). This showed that signal peptidase cleaves
PfEMP3 within seconds (,1 min) of protein synthesis (i.e.,
cotranslationaly), but this molecular species may be transient, as
it was not detected by immunoblot of 916-treated parasites, or in
PEXEL R.A mutant protein (Figure 3A–C). The radiolabeled
bands on the 35S-membrane were confirmed to be GFP-specific by
immunoblot (Figure S3C). PEXEL-cleaved PfEMP3-GFP (blue
arrow) was also evident 1 min after addition of label to the culture
medium and increased exponentially, indicating PMV cleavage
was also rapid and likely cotranslational (Figures 3E and S3D).
The proportion of PEXEL-cleaved protein increased slightly as
signal peptide-cleaved protein decreased (Figure 3E), suggesting
signal peptidase cleaves before PMV and that PMV may cleave
after signal peptidase.
Addition of 916 to parasites for 5 h prior to radiolabeling caused
accumulation of uncleaved PfEMP3-GFP in parasites (black
arrow), which was evident 1–2 min postlabeling (Figure 3F). After
a total of 15 min, the degree of PMV inhibition in parasites was
quantified by densitometry, and a 13-fold decrease in PEXEL
cleavage was observed compared to labeling without 916
(Figure 3G), indicating PMV was inhibited. The signal peptide-
cleaved and PEXEL-cleaved species were only weakly detectable
throughout the experiment and were not visible until 3–5 min
postlabeling (Figure 3F), compared to a stronger signal within 1–
2 min of labeling in the absence of inhibitor when the same
quantity of parasites was used (Figure 3E). This indicated that 916
significantly blocked PMV in P. falciparum and caused a delay in
protein synthesis, ER import, or N-terminal processing of
PfEMP3-GFP.
Processing of uncleaved PfEMP3-GFP within the PEXEL was
rescued after 15 min of culture in inhibitor-free medium (Figure
S3E,F), indicating that PMV is able to process full-length PfEMP3-
GFP.
WEHI-916 Kills P. falciparum at the Ring-Trophozoite
Transition
Having demonstrated that 916 can directly engage PMV in P.
falciparum–infected erythrocytes, the effect of the inhibitor on
parasite viability was examined by treating early ring parasites for
72 h and assessing parasitemia by flow cytometry. 916 killed
parasites with half maximal effective concentration (EC50) of 2.5–
5 mM (Figure 4A). Analogs 024 and 025 had negligible effect on
parasite viability at concentrations up to 20 mM, where 916
completely killed parasites; however, they had EC50 values of
66 mM and 30 mM, respectively, indicating they adversely affected
parasite growth at high concentrations. Because PEXEL process-
ing in parasites was unaffected by 024 and 025 treatment, even at
50 mM (Figure 3C), we conclude that the analogs impart toxicity at
high concentrations independent of PMV.
Figure 2. A PEXEL-mimetic inhibitor of PMV. (A) Nomenclature for each residue in the PEXEL substrate (circles) and each pocket of the PMV
active site (semicircles) with respect to the cleavage site (arrow). (B) Compound structures in this study include PMV inhibitor WEHI-916 and control
analogs WEHI-024 and WEHI-025. (C) Structural model of PfPMV bound to WEHI-916. Residues forming the S3 site, Try177, Glu179, and Glu215, form
interactions with the guanidine side chain of WEHI-916. The Leu side chain of WEHI-916 packs tightly against the side-chain groups of Ile116, Tyr177,
and Val227 in the S1 site. The statine hydroxyl forms hydrogen bonds with the two catalytic aspartate residues Asp118 and Asp365. (D) Inhibition of
PfPMV and PvPMV by WEHI-916 (blue) and weak activities of WEHI-024 (red) and WEHI-025 (brown). The grey box summarizes compound activity
against BACE-1 and Cathepsin D (CathD) and lack of toxicity against human HEpG2 cells and Human Foreskin Fibroblasts (HFF).
doi:10.1371/journal.pbio.1001897.g002
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Figure 3. WEHI-916 blocks PEXEL cleavage in P. falciparum. (A) Immunoblotting with a-GFP antibodies shows dose-dependent inhibition of
PEXEL cleavage of PfEMP3-GFP in parasites after 5 h 916 treatment at the indicated concentrations. Uncleaved protein (black arrow), PEXEL-cleaved
protein (blue arrow), and degraded chimera in food vacuole (GFP only) are labeled. PfEMP3-GFP R.A PEXEL mutant is shown as a size control. (B)
Inhibition of Plasmepsin V in P. falciparum
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To determine the stage of the parasite lifecycle that 916 exerted
its toxic effects, ring parasites were treated with 15 mM 916 for
increasing times through the 48 h cycle and then cultured in
inhibitor-free medium to a total of 72 h to see if parasites could
recover. Parasites grown in 916 for 1–20 h completely recovered
and grew like DMSO-treated controls; however, treatment for .
23 h adversely affected growth (Figure 4B), indicating the timing
of killing began after 20 h of age, at the ring-trophozoite
transition. Analogs 024 and 025 did not affect growth at any
parasite stage at the concentration used (15 mM), whereas
chloroquine and artemisinin killed parasites when added to rings
for only 30 min before addition of inhibitor-free medium
(Figure 4B, see 0 h). This indicated the controls either killed
rapidly (artemisinin) or were retained inside parasites and killed
later, as chloroquine is reported to kill trophozoites [22,23]. Both
profiles were clearly different than that observed for 916.
Toxicity by 916 after the ring-trophozoite transition was then
investigated by adding compound to parasites at different time
points through the 48 h cycle. At 48 h, inhibitor-free medium was
added and parasitemia for all conditions was determined at 72 h.
Toxicity decreased when 916 was added to parasites aged beyond
24 h and schizonts were resistant, indicating 916 did not affect
Immunoblot shows time-dependent inhibition of PEXEL cleavage in parasites. HSP70 is a loading control in (A) and (B) and densitometry of the
uncleaved band in each lane is shown below the blots in (A) and (B). (C) Immunoblot shows 916 treatment (20 and 50 mM for 5 h) causes
accumulation of uncleaved PfEMP3-GFP and KAHRP-GFP (black arrow), but 024 and 025 have no effect. R.A PEXEL mutant size controls are shown.
Signal peptide-cleaved species of KAHRP-GFP, but not PfEMP3-GFP, can be seen (red arrow). (D) Immunoblotting shows no defect (black arrow
indicates the predicted size of uncleaved protein; ,30 kDa) in signal peptide cleavage (red arrow; 27 kDa) of SERA5s-GFP, which lacks a PEXEL,
following treatment with 916, 024, or 025 (20 mM for 5 h). Aldolase was a loading control in (C) and (D). (E) 35S-Methionine/Cysteine labeling of
PfEMP3-GFP in parasites reveals the rapid rate of translation, ER import, and N-terminal processing in P. falciparum. Uncleaved (black arrow), signal
peptide-cleaved (red arrow), PEXEL-cleaved (blue arrow), and GFP-only (food vacuole) species are shown. Densitometry of each band per lane
(colored traces) is shown. Uncleaved (Un, black), signal peptide-cleaved (SP, red), and PEXEL-cleaved (PEX, blue) bands are shown as percentage of
total intensity per lane. Signal peptide-cleaved PfEMP3-GFP can be seen (red arrow, trace). (F) The experiment in (E) was performed after 916
treatment (20 mM for 5 h). Uncleaved protein was most abundant. Note low intensity of bands indicated by red and blue arrows and delay in their
appearance compared to (E). (G) Densitometry showing the ratio of PEXEL-cleaved to -uncleaved PfEMP3-GFP with or without 916 treatment
(determined using 15 min lanes in (E) and (F)).
doi:10.1371/journal.pbio.1001897.g003
Figure 4. WEHI-916 is lethal to P. falciparum 3D7. (A) Dose-response curves of P. falciparum 3D7 in the presence of 916, 024, or 025. EC50 values
are shown. (B) Parasitemia measured at 72 h (y-axis) following drug treatment at rings (30 min postinvasion) and replacement of the medium with
inhibitor-free medium (wash-out) at the time intervals shown (x-axis). (C) Parasitemia at 72 h (y-axis) after replacement of inhibitor-free medium with
media containing compounds at the intervals shown (x-axis). Parasitemia was determined by FACS in (A–C) and is relative to DMSO treatment in (B)
and (C). Concentrations are as follows: 916, 024, 025 (15 mM); CQ, chloroquine (150 ng/ml); ART, artemisinin (100 ng/ml). Error bars in (A–C) are mean
6SEM from duplicate experiments. (D) Light micrographs of Giemsa-stained parasites 16 and 32 h after drug treatment at early rings (15 mM). 916-
treated parasites failed to develop into trophozoites and did not recover. Ring parasites treated with E-64 (10 mM) [22] contained swollen food
vacuoles (arrow) due to inhibition of proteases involved in hemoglobin degradation; however, treatment with DMSO, 916, 024, or 025 did not cause
swelling. Swelling was quantified using 500 infected cells per condition in duplicate. Scale bar is 6 mm.
doi:10.1371/journal.pbio.1001897.g004
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merozoite egress or reinvasion (Figure 4C). As expected, the
addition of 916 to rings or early trophozoites was lethal
(Figure 4C). 024 and 025 did not have any effect on parasite
growth at the concentration used, whereas all parasite stages were
sensitive to chloroquine and artemisinin (Figure 4C).
Light microscopy of parasites following treatment of early ring
stages with 916 revealed a normal ring-stage morphology after
16 h; however, treatment for 32 h revealed a blockage in the ring-
trophozoite transition and the majority of parasites appeared
pyknotic and abnormal (Figure 4D). As greater than 50% of
parasites could not recover from this treatment condition (refer to
Figure 4B), the majority of parasites with this appearance were
dying or dead. Treatment with DMSO, 024, or 025 had no effect
on development by 32 h at 15 mM (Figure 4D). The morphology
of parasites treated with 916, 024, 025, and DMSO was distinctly
different from that observed for E-64–treated parasites, which
contained swollen food vacuoles from inhibition of haemoglobin
breakdown [24] (Figure 4D, arrow). This indicated that parasite
toxicity to 916 was unlikely due to off-target inhibition of those
food vacuole proteases. Collectively, the toxicity profile seen in the
above experiments defines the window of parasite death as
between 20 and 30 h, consistent with perturbed protein export
and erythrocyte remodeling [7].
To gain further insight into the effects of 916, 024, and 025 on
parasites, we assessed global protein synthesis following drug
treatment by radiolabeling parasite proteins. Treatment of
trophozoites with inhibitor for 5 h prior to radiolabeling had no
detectable effect on translation, even at 50 mM concentrations
(Figure S4A), indicating the compounds are not direct inhibitors of
the translation machinery. We next assessed protein synthesis
following 23 h of drug treatment of ring stage parasites (aged 1–
3 h old at the initiation of treatment). A minor reduction in
translation was observed following 916 treatment, but not 024 or
025 treatment, even at 50 mM (Figure S4B). A small but
concomitant decrease in the cytosolic protein, Aldolase, was also
evident by immunoblot following 916 treatment but not 024 or
025 treatment (Figure S4B), suggesting that parasites were
beginning to die from the 916 treatment (parasites ranged from
24–26 h old at this time point). Indeed, Giemsa smears following
treatment identified a small proportion of pyknotic parasites in the
population (results not shown). Treatment with Brefeldin A, which
prevents retrograde trafficking and ER exit, for 23 h severely
impaired translation and parasites appeared as dying rings (i.e.,
had not progressed to trophozoites). It is possible that PMV
inhibition by 916 treatment has a similar but weaker effect to BFA,
in that it causes the accumulation of uncleaved PEXEL precursors
in the ER, perturbing ER transport, and that this negatively affects
translation by an ER stress response [25]. An alternative possibility
is that translation was decreased slightly as a result of parasites
dying from 916-mediated impairment of erythrocyte remodeling.
Either way, the profile for 916 was different to that seen for 024
and 025, even at 50 mM, indicating the latter analogs likely kill
parasites via a different mechanism to 916.
Knockdown or Overexpression of PMV Modulates
Parasite Sensitivity to WEHI-916
Treatment of P. falciparum with 916 impaired PEXEL cleavage
and killed parasites, strongly suggesting that PMV is essential. To
investigate this phenotype further, conditional protein knockdown
was attempted in P. falciparum using the RNA-degrading glmS
ribozyme, which utilizes glucosamine (GlcN) as a cofactor [26].
DNA encoding 36 HA epitopes, a stop codon, and glmS was
incorporated in frame at the 39 of the PMV locus by homologous
recombination (Figure S5A). Correct genomic integration was
confirmed by immunoblot with anti-HA and anti-PfPMV antibod-
ies (Figure 5A). To activate glmS, GlcN was titrated into the culture
medium of trophozoites. From 75% to 90% PMV knockdown was
achieved after 48 h using 4–6 mMGlcN, but higher concentrations
adversely affected parasite HSP70 levels and were subsequently
avoided (Figure S5B). Addition of 5 mM GlcN to trophozoites for
24 h reduced PMV levels in subsequent rings by approximately
80% and trophozoites by ,90% but caused little knockdown in
parasites expressing inactive glmS (M9) (Figure 5B) [26]. Protein
export predominates in rings, when knockdown reached ,80%;
surprisingly, this substantial degree of knockdown did not signifi-
cantly affect PEXEL processing or parasite growth rate (p= .6250;
Figure 5C), indicating that the remaining PMV levels were sufficient
to enable export and sustain parasite development. This demon-
strates that PMV activity is potent in P. falciparum and that
knockdown to approximately 20% of wild-type levels could not
facilitate the characterization of PMV essentiality.
As 916 inhibited PMV in parasites (for example, by 13-fold,
Figure 3G), the additive effect of PMV knockdown plus 916
treatment was investigated. Parasites expressing PMVHA-glmS
were transfected with a construct encoding PfEMP3-GFP, and
PEXEL processing was assessed by immunoblot. PEXEL
processing of PfEMP3-GFP was barely affected by 48 h of PMV
knockdown alone (Figure 5D, see ‘‘+GlcN,’’ 0 mM 916); however,
addition of 916 to parasites for 5 h impaired PEXEL cleavage and
this was significantly enhanced following knockdown of PMV (e.g.,
by 50% at 20 mM; Figure 5D). The quantity of PfEMP3-GFP
expressed in the PMV knockdown (+GlcN) appeared slightly less
than in parasites without knockdown (2GlcN), whereas the
loading control HSP70 did not vary appreciably between
conditions (Figure 5D).
Parasites expressing PMVHA-glmS were next assessed for
toxicity to 916. The EC50 of 916 was reduced by 3.3-fold
following PMV knockdown compared to no knockdown
(Figure 5E). As a control, parasites expressing PMVHA-M9 were
treated with 916 in the presence or absence of GlcN; the EC50
reduced by 1.4-fold in the presence of GlcN, indicating it had a
minor effect. However, the enhancement of PEXEL cleavage
inhibition and 3.3-fold sensitization of parasites to inhibitor
following knockdown indicated that PMV is a direct target of
916 and that PMV inhibition is lethal to parasites.
We next investigated the possible effects of PMV overexpression
on parasite sensitivity to 916. Although parasites expressing
PfPMVHA do not overexpress enzyme, due to integration of the
construct at the endogenous PMV locus [13], parasites expressing
PvPMVHA from episomes also express wild-type levels of
endogenous enzyme (Figure 1B,C) and therefore contain addi-
tional, active PMV in the ER. To control for the carriage of
episomes and selection on WR99210, sensitivity to 916 was
compared between parasites overexpressing a similar construct on
episomes on WR99210 selection (encoding miniVarHA; see
Figure 1F). The EC50 of 916 was 1.9-fold greater for parasites
overexpressing PvPMVHA compared to parasites overexpressing
the control construct, and 1.4-fold greater than wild-type 3D7
parasites without WR99210 selection, indicating that PMV
overexpression had increased parasite resistance to 916 (Figure 5F).
PMV Inhibition Impairs Protein Export, PfEMP1 Display,
and Cytoadherence
Localization of parasite proteins in Maurer’s clefts (MCs), which
are parasite-induced membranous structures in the erythrocyte
that facilitate protein trafficking, enables accurate quantification of
export by immunofluorescence microscopy as the signal is
concentrated in puncta [27]. To study export in P. falciparum, we
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investigated a novel PEXEL-containing protein with two trans-
membrane domains and unknown function, called Hyp8
(MAL13P1.61/PF3D7_1301700) [14,28], that we hypothesized
may localize to MCs. Transgenic parasites expressing Hyp8-GFP
or Hyp8-HA were generated (Figure S6A). Immunoblotting
revealed that Hyp8 is expressed in rings (Figure S6B), and
immunofluorescence microscopy showed it is exported (Figure
S6C) and colocalizes with SBP1 in MCs (Figure 6A). Immunoe-
lectron microscopy confirmed that Hyp8 localizes in MCs
(Figure 6A, right). Three independent attempts to delete the
hyp8 gene were unsuccessful in this study, in addition to earlier
reported attempts [17], suggesting that Hyp8 may be an essential
exported protein.
The effect of 916 treatment on export in P. falciparum–infected
erythrocytes was then examined. Early ring parasites were treated
with inhibitor, and the subcellular Hyp8-GFP fluorescence was
quantified by immunofluorescence microscopy (Figure 6B). 916
treatment caused a dose-dependent decrease of Hyp8-GFP in
MCs (the GFP signal in puncta outside the EXP2-labelled
parasitophorous vacuole membrane) compared to DMSO and
024 treatment (p,.0001; Figure 6C). A small but significant
increase in nonexported GFP signal (the signal inside the EXP2
labeling) was observed as puncta of fluorescence internal to the
parasitophorous vacuole membrane following 916 treatment (p,
.0001; Figure 6D, see also arrows in B).
We next examined whether 916 treatment affected protein
secretion in P. falciparum–infected erythrocytes by measuring the
quantity of EXP2 signal at the parasitophorous vacuole membrane
following treatment. There was no statistical difference in EXP2
signal between treatments (p= .0977; Figure 6E), indicating 916
Figure 5. PMV knockdown or overexpression modulates sensitivity to WEHI-916. (A) Immunoblot with Ra-PfPMV antibodies shows
successful integration of the PMVHA-glmS or -M9 plasmid (M9 is an inactive glmS riboswitch control). The upper band (a-PfPMV blot) in lane 1
(denoted by *) is nonspecific. The same blot is shown below, probed with a-HA antibodies. HSP70 is a loading control. (B) Knockdown of PMV in P.
falciparum NF54 following 5 mM GlcN treatment. (Left) 0 h GlcN treatment of trophozoites causes no knockdown. (Center) The 24 h GlcN treatment
of trophozoites causes ,80% knockdown of PMV in subsequent rings compared to ‘‘2GlcN.’’ (Right) 48 h GlcN treatment of trophozoites causes
,90% knockdown of PMV in subsequent trophozoites compared to ‘‘2GlcN.’’ A small degree of knockdown is seen for M9, indicating GlcN has a
minor effect. (C) PMV knockdown by GlcN has no significant effect on parasite growth rate (p= .6250). Trophozoites were treated with 0 mM or 5 mM
GlcN and parasitaemia determined 48 h later by flow cytometry. Data are % growth ‘‘+GlcN’’ relative to ‘‘2GlcN,’’ and data are mean 6SEM of a
representative of duplicate experiments. (D) PEXEL processing of PfEMP3-GFP in P. falciparum parasites expressing PMVHA-glmS is reduced more by
916 treatment when PMV is knocked down [+GlcN (5 mM for 48 h prior to addition of 916)]. Densitometry shows the ratio of uncleaved to PEXEL-
cleaved protein in each lane beneath the blot. Note that PfEMP3-GFP expression is lower in ‘‘+GlcN’’ parasites despite relatively similar HSP70 levels.
(E) Dose-response curves of P. falciparum expressing PMVHA-glmS shows parasites have enhanced sensitivity to 916 following PMV knockdown (3.3-
fold decrease in EC50). Parasitemia was determined 72 h after addition of 916 to ring parasites with or without PMV knockdown (knockdown ring
parasites were obtained by adding 6 mM GlcN to trophozoites for 24 h). GlcN and 916 were maintained in the culture medium throughout. (F) Dose-
response curves of P. falciparum overexpressing PvPMVHA or a mini PfEMP1HA reporter (miniVarHA) in the presence of 5 nM WR99210 show
parasites have increased resistance to 916 when PMV is overexpressed (1.9-fold increase in EC50).
doi:10.1371/journal.pbio.1001897.g005
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specifically affected export but not secretion, under the conditions
used.
As Hyp8 localizes to MCs, we quantified the number of GFP-
positive MCs in infected cells following the drug treatments. The
mean number of clefts was significantly reduced by 916 treatment,
by up to 39%, compared to DMSO (p,.0001; Figure 6F).
Collectively, these data demonstrated that 916 dramatically
reduced the export of the PEXEL protein, Hyp8, and that MC
development was impaired following treatment.
An important function of exported proteins in remodeling and
virulence is to assemble the cytoadherence complex at the
erythrocyte surface [17]. Because export of Hyp8 and MC
formation was decreased following PMV inhibition, we investi-
gated whether trafficking of PfEMP1 was also affected by
quantifying its display on the surface of infected erythrocytes.
Ring-stage CS2-GFP parasites [29] selected for expression of the
PfEMP1 var2csa gene were treated with one of two sublethal doses
of 916 (Figure S7A), and surface-expressed PfEMP1 was measured
24 h postinvasion using PAM1.4 antibodies [30] that specifically
recognize VAR2CSA [31] by flow cytometry. PfEMP1 surface
expression decreased in a dose-dependent manner, by up to 55%,
following 916 treatment, but addition of DMSO and 025 had no
effect (Figure 6G). Parasitemia across all treatment conditions was
measured as GFP fluorescence by flow cytometry and was
approximately equal at 24 h, confirming parasite viability (Figure
S7B).
To evaluate whether decreased PfEMP1 surface expression
affected cytoadherence of infected erythrocytes, static binding
assays with purified CSA were performed [32,33]. Adhesion to
CSA was reduced by almost 50% following treatment with 916
compared to DMSO (p,.0001) and 025 had no effect (Figure 6H).
Collectively, this experimentally validates PMV activity as essential
for export of PEXEL-containing proteins, resulting in correct MC
formation and PfEMP1 assembly at the erythrocyte surface and
cytoadherence.
Discussion
Protein export allows malaria parasites to remodel their cellular
niche, and the protein machineries involved are obvious targets for
the development of inhibitors. PMV acts by cleaving the PEXEL
in the parasite ER and represents one such target. We developed a
PEXEL-mimetic compound that potently inhibits the activity of
PMV and, combined with protein knockdown or overexpression,
used it to demonstrate the essentiality of PMV for parasite survival
and its function for export.
The PMV inhibitor 916 mimics the transition-state of amide
bond proteolysis for PEXEL substrates using statine. Our PfPMV
structural model in complex with 916 outlines key interactions that
are likely necessary for inhibitor binding: the guanidine side chain
of Arg forms salt bridges with the acid of Glu179 and 215, and a p-
stacking interaction with Tyr177 in the S3 pocket of PMV. This in
part explains the necessity for Arg at P3 for PEXEL processing.
The P1 Leu side chain is encased by hydrophobic residues in the
S1 pocket formed in part by Ile116, Tyr177, and Val227,
explaining the importance of Leu in PMV binding.
916 potently blocked PMV activity in vitro and reduced PEXEL
cleavage, by up to 13-fold (Figure 3G), in cultured parasites,
demonstrating the inhibitor directly engaged PMV in the ER.
However, inhibition was time-dependent and incomplete at even
50 mM, indicating the inhibitor has suboptimal qualities. This may
be due to a combination of poor diffusion across membranes,
suboptimal final concentration in the ER, and the potent activity
of PMV in parasites, revealed in this study by knockdown of PMV
protein levels. Although further work is required to develop an
inhibitor with enhanced properties, 916 has proven sufficiently
active in parasites to examine PMV function and essentiality.
Previously, it has been shown that overexpression of a PfPMV
D118A mutant produced a dominant-negative effect on parasite
growth rate and protein export [12]. When we overexpressed an
alternate PfPMV mutant (D118A, D365A, F370A) on episomes in
P. falciparum, we observed a similar defect in parasite growth rate
and subsequent down-regulation of endogenous PfPMV expres-
sion levels, suggesting a negative feedback effect. A similar
negative feedback effect has been described for Toxoplasma gondii
myosin A [34]. Collectively, these PMV dominant-negative
mutants provide evidence that the enzyme is important for
parasite survival.
The effects of 916 were amplified when PMV was knocked
down and decreased when PMV was overexpressed, demonstrat-
ing that PMV is a target and that its inhibition is toxic to parasites.
Addition of 916 to ring stages arrested their transition to
trophozoites, between 20 and 30 h postinvasion, and parasites
could not recover. Although this phenotype is consistent with
death from impaired export and cellular remodeling, it is possible
that ER stress due to accumulation of uncleaved PEXEL proteins
in the organelle, and a decrease in translation, contributed [25].
The morphology of parasites treated with 916 was distinctly
different to E-64–treated parasites, which contained swollen food
vacuoles from inhibition of haemoglobin breakdown [24]. This
indicates that parasite toxicity to 916 was unlikely due to off-target
effects on food vacuole proteases. Although aspartyl protease
inhibitors are known to kill P. falciparum, it is not entirely clear
which aspartyl proteases (Plasmepsins) are essential (reviewed in
[35]). In Plasmodium, there are 10 Plasmepsins; I–IV are important
Figure 6. PMV inhibition impairs protein export, PfEMP1 display, and cytoadherence. (A) (Top) Immunofluorescent micrographs show
Hyp8-GFP is exported and localizes within puncta in the infected erythrocyte. (Middle) Hyp8-HA localizes within SBP1-containing MCs. (Right)
Immunoelectron microscopy shows Hyp8-HA localization at MCs. Scale bar is 100 nm. (B) Maximum intensity projection micrographs showing export
of Hyp8-GFP to MCs and secretion of EXP2 to the parasitophorous vacuole membrane following treatment with DMSO or 916 (50 mM). Puncta of
nonexported GFP within the parasite and vacuole is shown (arrows). (C) GFP intensity in MCs (outside EXP2 signal) and within the parasite and
parasitophorous vacuole (inside EXP2 signal) was quantified following drug treatment (see Materials and Methods) and is presented as a ratio:
exported= ratio outside/inside EXP2. The number of infected cells counted (n) is shown. (D) GFP within the parasite and parasitophorous vacuole
(inside EXP2 signal) was quantified across treatments and is presented as a ratio: nonexported= ratio inside/outside EXP2. (E) EXP2 intensity in the
parasitophorous vacuole membrane (red) was quantified across treatments and is presented as average (threshold) signal. (F) The number of GFP-
positive MCs per infected erythrocyte was quantified across treatments. Error bars represent the mean 6SEM, and p values were determined by
ANOVA in (C–F). (G) Surface-exposed PfEMP1 (VAR2CSA) on infected erythrocytes was measured following inhibitor treatment by FACS using
monoclonal human PAM1.4 serum [30]. Geometric mean fluorescence of .100,000 cells per condition are shown relative to no treatment. Parasites
received inhibitor at 15 mM for 23 h (15 mM) or 50 mM for 12 h followed by a reduction to 15 mM for 11 h (50.15 mM). Shown is a single
representative of duplicate experiments. Raw FACS data are presented in Figure S7. (H) Adhesion of infected red blood cells (iRBCs) to chondroitin
sulfate A (CSA) under static conditions. Adherent iRBCs were counted in ten 0.28 mm2 fields of view per sample from triplicate samples and are
shown as number of iRBCs per mm2. Shown is a single representative of duplicate experiments. Data represent mean 6SEM. 95% confidence
intervals are shown (grey dashed lines). 916 significantly reduced adhesion to CSA p,.0001.
doi:10.1371/journal.pbio.1001897.g006
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enzymes for haemoglobin degradation by P. falciparum, but the
genes encoding each enzyme can be deleted from the genome,
indicating they are not essential [36]. The death of P. falciparum
following 916 treatment is therefore unlikely to be due to
inhibition of these Plasmepsins. A survey of P. falciparum
transcriptomes [37] suggests that, of the remaining five Plasmep-
sins (VI–X), only VII, IX, and X are expressed by asexual blood-
stage parasites; however, VII and X are expressed at very low
levels. Thus, Plasmepsin IX (PMIX) is considered the primary
possible off-target in our study. However, we have shown
previously that HA-tagged PMIX does not cleave the PEXEL
motif [13], and although the enzyme itself possesses a PEXEL
motif, its function and essentiality is currently unknown.
Analogs of 916 that mimic noncleavable PEXEL mutant
sequences (R.K, L.I) were ineffective inhibitors of PMV in vitro
and had no discernable effect on parasites at concentrations that
916 inhibited PEXEL cleavage in parasites and was lethal (i.e., ,
20 mM). However, at concentrations above 20 mM they were toxic
to parasites and possessed EC50 values between 6- and 26-fold less
potent than 916. At 50 mM, we saw no evidence of PMV or signal
peptidase inhibition, export or secretion defects, or global effects
on translation caused by 024 or 025. This suggests that they hit a
target(s) distinct from 916.
The rapid rate of protein synthesis, ER import, signal peptide
processing, and PEXEL cleavage in P. falciparum was determined
for the first time. The rate was within immeasurable seconds after
translation, consistent with both signal peptidase and PMV activity
occurring cotranslationaly. The full-length PEXEL is thus only
present in the proprotein very transiently, making its function in
export even more remarkable. This underscores the importance of
the remaining PEXEL residues (xE/Q/D) in export following
processing [11]. The PEXEL has been suggested to function
independent of PMV by binding PI3P in the ER, and ER-derived
transport vesicles, via the PEXEL Arg [38]. The rate at which
PEXEL processing occurred in our experiments is inconsistent
with this hypothesis, as the PEXEL Arg is cleaved off during, or
soon after, ER entry. It is also challenging to envisage how the
PEXEL Arg could dock within the S3 pocket of PMV, where it is
required for proteolytic cleavage, if it is bound to the ER
membrane via an interaction with PI3P.
This work has characterized a novel PEXEL protein, Hyp8,
which is exported in the early ring-stage to MCs. The function of
Hyp8 is unknown, but the hyp8 gene was refractory to deletion
and may be essential. 916 treatment dramatically impaired Hyp8
export, resulting in some accumulation in the parasite and
possibly degradation. It is unknown whether the reduced export
of Hyp8 directly contributed to parasite death; however, the
phenotype demonstrates the importance of PMV in export of
PEXEL-containing cargo. This is further supported by the
decrease in MC numbers observed following 916 treatment; MC
formation is known to require exported proteins (reviewed in
[20]). The secretion of EXP2 to the parasitophorous vacuole
membrane was unaltered by 916 treatment, demonstrating that
the effects of 916 were specific to export. A clear defect in
PfEMP1 surface exposure and cytoadherence was also observed
following 916 treatment. PfEMP1 is unlikely to be a PMV
substrate [18], but its trafficking through the erythrocyte and
onto the surface requires at least six PEXEL-containing proteins
[17]; thus, the demonstration that PMV activity is essential for
PfEMP1 surface expression and cytoadherence is consistent with
the current literature and validates the specificity of the inhibitor.
Further, it directly demonstrates the importance of PMV at the
first step in the export pathway for cellular remodeling that leads
to virulence.
P. vivax is an important global pathogen that cannot be cultured
in the laboratory, and novel therapeutic targets for this enigmatic
parasite are urgently needed. This work has characterized PMV
from P. vivax for the first time. PvPMVHA possesses the trafficking
information to localize to the ER and has similar PEXEL cleavage
activity and specificity to PfPMV. This indicates that PMV
function is to cleave the PEXEL motif of exported proteins across
Plasmodium spp., and future compounds that block PMV are likely
to affect multiple Plasmodium spp. Protein export also occurs in
gametocytes [28] and liver stages [39], and 916 may aid the
characterization of PMV in these stages.
A putative PMV homolog, ASP5, is present in Toxoplasma and
localizes to the Golgi [40]. Recent evidence suggests that some
exported T. gondii proteins contain a PEXEL [41], and some are
cleaved in a manner that requires the conserved PEXEL residues
[42]. The PEXEL protease may therefore be conserved beyond
the Plasmodium genus, and PMV and its homologs may therefore
represent multistage, multispecies antiparasitic targets of the
future.
Materials and Methods
Plasmids, Parasites, and Antibody Production
P. falciparum 3D7 parasites expressing PfPMVHA,
PfPMVmutHA, and PfEMP3-GFP were generated previously
[13], as was KAHRP-GFP [18] and CS2-GFP [29]. DNA
encoding PvPMV or PvPMVmut fused to 36 HA tags was
synthesized (Epoch Biosciences) and cloned into pGlux.1 [11] with
XhoI and PacI, removing GFP. DNA encoding miniVarHA
[PfEMP1 NTS (residues 1–51) fused to SVL-TM-ATS (residues
2640–2734) of IT4 VAR2CSA] was synthesized (Epoch Biosci-
ences) and cloned into pGlux.1 with XhoI and PacI. DNA encoding
the signal peptide of SERA 5 (PFB0340c) (residues 1–25) or the
entire hyp8 gene (MAL13P1.61) was amplified from P. falciparum
gDNA and cloned in frame with GFP in pGlux.1 using XhoI and
XmaI. For HA tagging Hyp8, the 39 800 bp of hyp8 was cloned into
p1.2-SHA [13] (also called pHA3; [43]) using BglII and PstI. For
tagging PfPMV with HA-glmS in P. falciparum NF54, the 39
1144 bp of PMV was cloned into pPTEX150-HA-glmS, which
consisted of the glmS riboswitch from pGFP_glmS [26] cloned into
pHA3 using BglII and PstI to replace the PTEX150 gene with
PMV, generating pPMVHA-glmS. For tagging PfPMV with HA-
M9, the M9 insert from pGFP_M9 [26] was cloned into
pPMVHA-glmS to generate pPMVHA-M9. To express PfEMP3-
GFP in P. falciparum NF54 harboring PMVHA-glmS, the
dihydrofolate reductase selection cassette in pPfEMP3Glux.1
[13] was replaced with blasticidin deaminase using BamHI and
HindIII prior to transfection. P. falciparum transfectants were
selected with 5 nM WR99210 (Jacobus Pharmaceuticals) and/or
2 mg/ml Blasticidin S (Calbiochem) and grown in O+ human
erythrocytes as described [18]. CS2-GFP parasites preferentially
expressing the var2csa gene (PFL0030c/PF3D7_1200600) were
selected every 2 wk by enriching for knob-positivity with gelatin
[44] and panning for CSA-binding [45]. Ra-PfMV antibodies
were generated by immunization of rabbits with recombinant
PfPMV generated previously [13] and collecting serum during
four boost immunizations. Affinity-purified polyclonal rabbit a-
Hyp8 antibodies were generated by Genscript using the peptide
N-55ETEQSTPAKPEPTE68-C.
PMV-Agarose, PEXEL Cleavage Assays, Mass
Spectrometry, and Parasite Growth Assays
PMV-agarose was prepared by adding a-HA-agarose (Sapphire
Bioscience) to parasite lysates, prepared by sonication in 1%
Inhibition of Plasmepsin V in P. falciparum
PLOS Biology | www.plosbiology.org 12 July 2014 | Volume 12 | Issue 7 | e1001897
Triton X-100/PBS, for 1 h before extensive washing in same
[12,13]. PEXEL cleavage assays (20 ml total volume) consisted of
0.2 ml PMV-agarose in digest buffer (25 mM Tris, 25 mM MES,
pH 6.4) with 1.5 mM FRET peptide substrate (DABCYL-
RNKRTLAQKQ-E-EDANS, DABCYL-RNKATAAQKQ-E-
EDANS, LifeTein; DABCYL-RNKKTLAQKQ-E-EDANS,
DABCYL-RNKRTIAQKQ-E-EDANS; Mimotopes) 6 inhibitor.
Samples were excited at 340 nm and fluorescence emission
measured at 492 nm using an Envision fluorescence plate reader
(Perkin-Elmer) heated to 37uC for 150 min. Samples were shaken
between measurements. For determination of the peptide cleavage
position by PvPMVHA, the fluorogenic peptide (DABCYL-
RNKRTLAQKQ-E-EDANS), representing the wild-type
KAHRP PEXEL sequence, was incubated with and without
PvPMVHA at 37uC for 48 h. Products of the incubation were
detected by a molecular formula algorithm using an Agilent 6200
TOF/6500 series mass spectrometer.
Parasite growth assays were performed in 96-well plates by
incubating highly synchronous ring-stage P. falciparum 3D7 or
NF54 parasites with compounds solubilized in DMSO at the
indicated concentrations for the indicated times. In the case of
dose-response curves, medium was kept for the entire experiment;
in the case of curves in Figure 4B,C, medium was replaced with
inhibitor-free medium at 48 h postinfection. Parasitaemia was
always determined at 72 h by flow cytometry. To knock down
PMV, GlcN (Sigma) was added to trophozoites and drug curves
initiated by adding compound at subsequent rings (24 h) for 24–
72 h.
Immunoblots
Trophozoites (30–34 h) expressing PfEMP3-GFP, KAHRP-
GFP, or SERA5s-GFP were magnet-purified (Miltenyi Biotech),
incubated with inhibitors in 400 ml total volume at 37uC for 1–5 h,
treated with 0.09% saponin containing inhibitor, and washed
pellets were solubilized in Laemmli’s buffer, boiled for 3 min, and
frozen at 220uC. Proteins were separated by SDS-PAGE,
transferred to nitrocellulose and blocked in 10% skim milk/PBS-
T, and probed with rat a-HA (Roche 3F10; 1:1,000), mouse a-
GFP (Roche; 1:1,000), rabbit a-Aldolase (1:1,000), rabbit a-
HSP70 (1:4,000), rabbit a-PfPMV (1:1,000), or rabbit a-Hyp8
(1:500) primary antibodies followed by horseradish peroxidase-
conjugated secondary antibodies (Silenius) and detected by
enhanced chemiluminescence (Amersham).
Protein Radiolabeling, Pulse-Chase, and Densitometry
Whole parasite proteins were radiolabeled by culturing magnet-
purified trophozoites (wild-type 3D7 or expressing PfEMP3-GFP)
in Met/Cys-free medium for 30 min at 37uC before addition of
800 mCi/ml 35S-Met/Cys (Perkin/Elmer) to the medium for the
indicated times. Pellets were snap frozen in ethanol/dry ice bath
and stored at 280uC. For radiolabeling in the presence of PMV
inhibitor, parasites were treated with 20 mM WEHI-916 for 5 h
before labeling commenced. For pulse-chases, proteins were
radiolabeled in the presence or absence of inhibitor, as above,
before further culture in radiolabel-free, inhibitor-free complete
medium for the indicated times at 37uC before snap freezing.
Frozen samples were either solubilized in Laemmli’s buffer (Figure
S4) or solubilized in 1% Triton X-100/PBS with protease
inhibitor cocktail (Roche) and PfEMP3-GFP species immunopur-
ified with a-GFP agarose (MBL) at 4uC for 2 h (Figures 3 and S3),
and proteins were resolved by SDS-PAGE, visualized by
autoradiography (7-d exposures), and quantified using a GS-800
Calibrated Densitometer (Bio-Rad).
Microscopy, Quantification of Hyp8 Export, and Statistical
Analyses
For immunofluorescence microscopy, smears were fixed in cold
acetone:methanol (90:10) and probed with rabbit Ra-PfPMV
(1:750), mouse Ma-PfPMV (1:25), rabbit a-EXP2 (1:200), rat a-
HA (Roche 3F10; 1:50), mouse a-GFP (Roche; 1:500), or rabbit a-
Hyp8 (1:200) antibodies followed by Alexa Fluor 488- or 594-
conjugated secondary antibodies (Molecular Probes; 1:1,000).
DNA was stained with 49-6-Diamidino-2-phenylindole (DAPI) at
0.2 mg/ml. Samples were viewed on a Deltavision Elite micro-
scope and images collected with a Coolsnap HQ2 CCD camera
through an Olympus 1006 UPlanSApo NA1.4 objective with
SoftWorx software. Images were assembled with ImageJ Fiji 1.47d
and Adobe Photoshop CS6 v13.0 x64. Light and immunoelectron
microscopy was performed as described in [46].
For quantification of events in cells infected with parasites
expressing Hyp8-GFP, highly synchronous ring-stage parasites
engineered to express Hyp8-GFP from the CRT promoter were
obtained by incubation of erythrocytes with viable merozoites for
15 min [47] and treated with 20 or 50 mM 916 30 min
postinvasion for 13 h (until Hyp8-GFP expression from the CRT
promoter had occurred for 1 h). Smears were fixed in 90:10
acetone:methanol, labeled with anti-GFP and anti-EXP2 antibod-
ies, and Z-stacks captured on a Deltavision Elite microscope using
a 1006 objective. Over 40 Z-stacks per condition were imaged
using the same exposure settings to allow quantitative analysis
between groups.
Hyp8 export. A parasite mask was generated by combining
the signals from the maximum intensity projections of the nuclear
(DAPI) and parasitophorous vacuole membrane (EXP2) images
and setting a manual threshold. A whole infected erythrocyte mask
was produced by manually tracing the cell boundary using the
DIC image. Average GFP intensity measurements were deter-
mined on masked summed intensity projections of the GFP images
using MetaMorph Image Analysis suite (Molecular Devices, USA).
Ratios of the average intensity measurements of GFP inside the
parasite (inside EXP2) versus exported to the erythrocyte (outside
EXP2) were determined.
EXP2 secretion. The EXP2 signal was measured by masking
the infected cell using a watershed transform on the summed and
filtered red signal, seeded by the DAPI-positive parasite.
Number of MCs. Clefts were counted using ImageJ’s ‘‘Find
Maxima’’ function to detect local maxima in the green signal
within the masked cell region.
Statistics. Kinetics and statistical analyses were performed
with GraphPad Prism 6.0b. Single comparisons were performed
using t test and multiple comparisons by ANOVA.
916 Dosage Regime and PfEMP1 Surface Display
As 916 treatment has adverse affects on parasites after 24 h, a
sublethal dosing regime was developed (see Figure S7) to maximize
the inhibitor effect while ensuring parasites remained viable 24 h
postinvasion when surface-exposed PfEMP1 was measured.
Treatment with .15 mM for 23 h or with 50 mM for .12 h
postinvasion prior to decreasing to 15 mM adversely affected
parasite growth and was avoided.
To measure PfEMP1 display, highly synchronous ring-stage
CS2-GFP parasites preferentially expressing VAR2CSA (see
Plasmids, Parasites, and Antibody Production) were obtained by
incubation of erythrocytes with viable merozoites for 15 min [47],
and parasites were treated with 916, 025, or DMSO using the
dosage regime above. At 24 h postinvasion (presence of inhibitor
for no more than 23 h), erythrocytes were incubated with human
monoclonal PAM1.4 serum [30] (1:200) to label VAR2CSA
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followed by goat anti-human IgG Biotin-conjugated secondary
antibodies (Invitrogen) (1:200) and Alexa Fluor-633 Streptavidin-
conjugated tertiary antibodies (Invitrogen) (1:500) for 30 min each.
Labeled cells were washed with 0.1% casein/PBS and analyzed on
a FACSCalibur cytometer (Becton-Dickinson, USA). Fluorescence
in channel FL1 was used to measure parasite-infected erythrocytes
(GFP), and fluorescence in channel FL4 was used to measure
bound PAM1.4 IgG antibodies (Alexa 633) for each sample. The
geometric mean fluorescence of uninfected erythrocytes (treated
with secondary and tertiary but not primary antibodies) was
deducted from the geometric mean fluorescence of infected
erythrocytes using .100,000 cells per condition. Experiments
were conducted in duplicate. Analyses were performed using
FlowJo 8.8.7 (Tree Star, USA).
CSA Adherence Assay
Adhesion assays were performed as described previously
[32,33]. Briefly, CSA (Sigma) was spotted at 50 mg/ml in triplicate
into petri dishes, incubated overnight at 4uC, and blocked in 1%
casein/PBS for 2 h. Inhibitor-treated erythrocytes were added to
CSA-coated dishes and incubated for 45 min at 37uC. Dishes were
washed four times with 5 ml warm RPMI-HEPES, fixed in 2%
paraformaldehyde for 2 h, stained with 10% Giemsa for 15 min,
and the number of adherent erythrocytes per mm2 quantified by
light microscopy counts. Assays were performed in triplicate.
PMV Modeling and Inhibitor Synthesis
This information is presented in Materials and Methods S1.
Supporting Information
Figure S1 ClustalW alignment of PMV from P. falciparum and P.
vivax. The putative P. vivax PMV protein sequence (PvPMV;
PVX_116695) was identified by homology searches using the P.
falciparum PMV sequence (PfPMV; Pf3D7_1323500). A ClustalW
alignment shows they share 82.2% similarity (485/590) and 54.7%
identity (323/590) over the full-length sequences including gaps.
The predicted signal peptide is shown below the red line, the
catalytic dyads are shown in bold with catalytic aspartic acid
residues below the red circles, and the C-terminal transmembrane
domain is shown below the black line. Four insertions in PfPMV
are absent from PvPMV, accounting for their ,7.5 kDa size
difference.
(TIF)
Figure S2 Purity, substrate cleavage position, and kinetics of
PMVHA-agarose. (A) Immunoblot of immunopurified PfPMVHA
or PvPMVHA eluted from a-HA-agarose with reducing sample
buffer shows that the sample preparations contain PMVHA that
are species-specific. (Left) a-HA antibodies show purification of
PfPMVHA (69.1 kDa once signal peptide removed) and
PvPMVHA (60.9 kDa once signal peptide removed) from parasite
lysates. (Right) The blot on the left was stripped and reprobed with
Ra-PfPMV antibodies. Only HA-tagged PfPMV but not endog-
enous wild-type PfPMV (64.4 kDa once signal peptide removed)
was present in the PfPMV-agarose preparation (lane 1). In lane 2,
the Ra-PfPMV antibody does not cross-react with PvPMVHA
(60.9 kDa) and does not identify any endogenous wild-type
PfPMV in the PvPMVHA-agarose preparation. The black spot
on the right of the blot (*) is a nonspecific artefact, not PvPMVHA.
(B) LC chromatogram (214 nm) of the fluorogenic KAHRP
PEXEL peptide after incubation at 37uC for 48 h with
PvPMVHA (red trace) and without PvPMVHA (blue trace). The
products of processing by PvPMVHA can be observed: the C-
terminal cleavage product NH2-AQKQ-E(EDANS)NH2 (Rf
0.66 min) and the N-terminal fragment DABCYL-RNKRTL-
OH (Rf 1.7 min) are labeled. The unprocessed fluorogenic peptide
DABCYL-RNKRTLAQKQ-E(EDANS)NH2 is shown to possess
an approximately similar Rf (1.7 min) to the processed N-terminal
fragment. MS-TOF analysis shows (C) the C-terminal cleavage
product (QAQKQ-E-EDANS), (D) the N-terminal cleavage
product (DABCYL-RNKRTLQ), and (E) the unprocessed
fluorogenic KAHRP peptide. (F) Michaelis–Menten curve show-
ing the rate of cleavage (relative fluorescence units per min) of
increasing concentrations of fluorogenic KAHRP PEXEL peptide
by PfPMVHA (squares) and PvPMVHA (circles) after 2 h. The
data were used to derive Km values reported in the text.
(TIF)
Figure S3 WEHI-916 inhibits PMV in P. falciparum. (A)
Immunoblot with anti-GFP antibodies shows that cleavage
inhibition of PfEMP3-GFP by 916 treatment (20 mM 916 for
4 h) is rescued after culture in inhibitor-free medium for the
indicated times. Densitometry of the uncleaved band is shown
below each lane, and HSP70 is a loading control. (B) Immuno-
fluorescence micrograph of P. falciparum expressing SERA5s-GFP,
which lacks a PEXEL, showing the chimera is secreted to the
parasitophorous vacuole. (C) Immunoblot of the 35S-membrane in
Figure 3E with anti-GFP antibodies confirms the uncleaved (black
arrow), signal peptide-cleaved (red arrow), PEXEL-cleaved (blue
arrow), and GFP-only bands in Figure 3E are indeed GFP-specific.
(D) Modified exposure of the blot in Figure 3E, showing the
presence of signal peptide-cleaved (red arrow) and PEXEL-cleaved
(blue arrow) protein 1 min after addition of label to the culture
medium. (E) Pulse chase of PfEMP3-GFP in P. falciparum–infected
erythrocytes. (Left) Radiolabeling of PfEMP3-GFP for 5 min
(pulse) followed by culture in label-free, inhibitor-free medium for
the indicated times (chase) revealed little uncleaved protein (black
arrow) and that signal peptide-cleaved protein was more abundant
than PEXEL-cleaved protein. The proportion of PEXEL-cleaved
protein increased after 3 min of the chase, as the proportion of
signal peptide-cleaved protein decreased, demonstrating that PMV
can cleave the signal peptide-cleaved protein. (F) Accumulation of
uncleaved radiolabeled PfEMP3-GFP in parasites following 5 h of
916 pretreament (20 mM) was reduced after 5–15 min of the chase
in label-free, inhibitor-free medium. A concomitant increase in the
proportion of PEXEL-cleaved protein was observed from 5 min
onward as the quantity of uncleaved protein sharply decreased,
demonstrating that PMV can cleave the full-length protein.
(TIF)
Figure S4 Effect of WEHI-916 on global protein translation in
P. falciparum. (A) Magnet-purified trophozoites treated with DMSO
or 916, 024, 025 (15 or 50 mM), or Brefeldin A (BFA; 10 mg/ml)
for 5 h prior to labeling parasite proteins with 35S-Methionine/
Cysteine for 15 min reveal no defect in global protein synthesis.
Aldolase levels were examined by immunoblot of the same blot as
a loading and viability control. (B) Ring parasites treated with
DMSO or 916, 024, 025 (15 mM or 50 mM for 12 h followed by
15 mM for 11 h (50.15 mM)) or BFA (5 mg/ml) for 23 h prior to
labeling parasite proteins with 35S-Methionine/Cysteine for
15 min reveals no defect in global protein synthesis for DMSO,
024, or 025. A slight reduction in translation is seen with 916
treatment, and immunoblotting revealed that Aldolase levels were
also reduced following 916 treatment, suggesting either that
accumulation of uncleaved PEXEL precursors in the ER has a
negative effect on translation or that a proportion of parasites were
beginning to die or both. BFA treatment, which halts retrograde
transport and ER exit, severely reduced translation in parasites
and Aldolase levels, suggesting negative feedback on protein
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synthesis occurs in parasites with blocked ER transport. The effect
of 916 was clearly different to that of 024 and 025, suggesting the
latter impart toxicity independent of PMV at concentrations .
20 mM.
(TIF)
Figure S5 Effect of GlcN addition to P. falciparum cultures. (A)
Schematic of allelic exchange to introduce 36HA epitopes and
glmS riboswitch into the 39 of the PMV gene in P. falciparum NF54.
(B) P. falciparum trophozoites were treated with 0–10 mM GlcN for
48 h and PMV levels assessed by immunoblot with a-PfPMV
antibodies. HSP70 was used as a loading control and to assess
parasite viability in the presence of GlcN. Densitometry of the
PMV and HSP70 bands is shown below the blots. We utilized 4–
6 mM GlcN for all future experiments.
(TIF)
Figure S6 Hyp8 epitope tagging, expression, and export. (A)
Schematic of Hyp8-GFP and Hyp8-HA proteins generated in this
study and their sizes. (B) Time course of 3D7-Hyp8-HA protein
expression from the endogenous locus in P. falciparum. Immunoblot
of parasite-infected erythrocyte lysates with a-HA and rabbit a-
Hyp8 antibodies shows the protein is expressed from 8 h
posterythrocyte invasion and protein levels are maintained
throughout the parasite lifecycle. Aldolase was used as a loading
control. The blot validates that rabbit a-Hyp8 antibodies are
specific. (C) Immunofluorescence micrograph of ring-stage
parasite-infected erythrocytes probed with a-HA and rabbit a-
Hyp8 antibodies shows the protein is exported and localizes to
punctate structures (confirmed to be MCs in Figure 6A).
(TIF)
Figure S7 PfEMP1 expression on the erythrocyte surface
measured by flow cytometry. (A) Inhibitor treatment regime used
to measure PfEMP1 surface display on infected erythrocytes while
maintaining parasite viability. Early ring parasites receive inhibitor
at 15 mM for 23 h (15 mM), or 50 mM for 12 h followed by a
reduction to 15 mM for 11 h (50.15 mM) to maintain parasite
viability. (B) Measurement of surface-exposed PfEMP1 on
erythrocytes infected with CS2-GFP parasites by flow cytometry
using monoclonal human PAM1.4 serum (specific for VAR2CSA).
In each plot, the lower left gate corresponds to GFP-negative
(uninfected) erythrocytes. The upper left gate corresponds to GFP-
positive, surface PfEMP1-negative erythrocytes. The upper right
gate corresponds to GFP-positive, surface PfEMP1-positive
erythrocytes. Using all GFP-positive cells (upper left and right
gates) the geometric mean fluorescence of PAM1.4-labelled cells
(channel FL4) was quantified (i.e., the gradient of surface PfEMP1
positivity) from a total input of .100,000 infected and uninfected
cells per condition. Parasitemia corresponds to all GFP-positive
cells. Plot of uninfected erythrocytes is also shown. Upper panels
(‘‘With PAM4.1’’) contain cells labeled with primary, secondary,
and tertiary antibodies, while lower panels (‘‘Without PAM4.1’’)
contain cells labeled with secondary and tertiary antibodies only,
to show specificity.
(TIF)
Materials and Methods S1 Supplementary Materials and
Methods.
(DOCX)
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